KalVista Pharmaceuticals to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Author:

KalVista Pharmaceuticals, a clinical stage pharmaceutical company focused on the discovery and development of oral protease inhibitors, has announced that its management will be participating in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference. The conference is scheduled to take place on Wednesday, April 10, 2024, at 10:15 a.m. ET.

During the fireside chat, KalVista Pharmaceuticals’ management will discuss the company’s progress and upcoming milestones. A live webcast of the presentation will be available on the company’s website, and an audio archive will be accessible for 30 days following the event.

KalVista Pharmaceuticals is dedicated to the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. The company recently disclosed positive phase 3 data for its oral therapy sebetralstat, which is designed to be taken on-demand. KalVista plans to submit a new drug application to the U.S. Food and Drug Administration (FDA) for sebetralstat in the first half of 2024, with plans to seek approval in Europe and Japan later in the same year.

In addition to sebetralstat, KalVista Pharmaceuticals is also working on an oral Factor XIIa inhibitor program that aims to improve the treatment options for people living with hereditary angioedema (HAE) and other diseases.

For more information about KalVista Pharmaceuticals and its ongoing developments, interested parties can visit the company’s website at www.kalvista.com.

This press release may contain forward-looking statements, and readers are advised to refer to the company’s filings with the Securities and Exchange Commission for a detailed discussion of potential risk factors that could affect KalVista Pharmaceuticals’ business and financial results. The company undertakes no obligation to update any forward-looking statements, whether written or oral, that may be made in the future.

KalVista Pharmaceuticals operates in the pharmaceutical industry, specifically focusing on the discovery and development of oral protease inhibitors. Protease inhibitors are molecules that inhibit the activity of enzymes called proteases, which play a crucial role in various cellular processes.

The market for protease inhibitors is projected to experience substantial growth in the coming years. Factors such as the increasing prevalence of diseases with unmet medical needs, advancements in drug discovery technologies, and the rising demand for targeted therapies are driving the demand for protease inhibitors.

In particular, KalVista Pharmaceuticals is developing sebetralstat, an oral therapy for on-demand use. The company recently released positive phase 3 data for sebetralstat, positioning it as a promising drug candidate. KalVista plans to submit a new drug application to the FDA in the first half of 2024, with subsequent plans to seek approval in Europe and Japan.

In addition to sebetralstat, KalVista Pharmaceuticals is also working on an oral Factor XIIa inhibitor program. This program aims to improve treatment options for individuals with hereditary angioedema (HAE) and other related diseases. By targeting Factor XIIa, an enzyme involved in blood clotting, KalVista Pharmaceuticals aims to develop innovative therapeutics that address the unmet needs of patients.

For further information on KalVista Pharmaceuticals and its ongoing developments, interested individuals can visit the company’s website at www.kalvista.com (URL not modified).

It is worth noting that while the forward-looking statements in this article provide insights into the company’s plans and expectations, there are risks and uncertainties that could impact KalVista Pharmaceuticals’ business and financial performance. Interested readers are advised to refer to the company’s filings with the Securities and Exchange Commission to gain a comprehensive understanding of these potential risk factors.

Overall, KalVista Pharmaceuticals is actively working towards the advancement of oral protease inhibitors, aiming to address the significant unmet medical needs in various diseases. With the positive phase 3 data for sebetralstat and ongoing research in the Factor XIIa inhibitor program, the company is paving the way for potential breakthroughs in the pharmaceutical industry.